A methodological framework for drug development in rare diseases. The CRESim program: Epilogue and perspectives

Area of Science:

• Pharmacometrics
• Clinical Trial Design
• Rare Disease Drug Development

Background:

• Drug development for rare diseases faces challenges due to small patient populations.
• Optimizing clinical trial design is crucial for efficient rare disease drug development.

Purpose of the Study:

• To propose a generalizable strategy for optimizing clinical drug development in rare diseases.
• To leverage modeling and simulation alongside dataset analysis.

Main Methods:

• Simulation of a virtual patient population based on real data.
• Modeling of disease pathophysiology and pharmacokinetic-pharmacodynamic (PK/PD) relationships.
• Simulation of various randomized controlled trial (RCT) designs and multi-dimensional analysis of results.

Main Results:

• The proposed strategy integrates virtual patient populations, PK/PD modeling, and simulated RCTs.
• A multi-dimensional analysis approach was used to evaluate RCT durations and treatment effect estimation precision.
• Modeling and simulation were demonstrated as supplementary tools for drug development.

Conclusions:

• The CRESim project provides a framework for optimizing rare disease drug development through simulation.
• Modeling and simulation can enhance the efficiency and precision of clinical trial design.
• These computational methods are valuable adjuncts but cannot replace traditional RCTs in real patients.